Angiogenesis Imaging Using 68Ga-RGD PET/CT: Therapeutic Implications

Jae Seon Eo, Jae Min Jeong

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Angiogenesis imaging is important for diagnostic and therapeutic treatment of various malignant and nonmalignant diseases. The Arg-Gly-Asp (RGD) sequence has been known to bind with the αvβ3 integrin that is expressed on the surface of angiogenic blood vessels or tumor cells. Thus, various radiolabeled derivatives of RGD peptides have been developed for angiogenesis imaging. Among the various radionuclides, 68Ga was the most widely studied for RGD peptide imaging because of its excellent nuclear physical properties, easy-to-label chemical properties, and cost-effectiveness owing to the availability of a 68Ge-68Ga generator. Thus, various 68Ga-labeled RGD derivatives have been developed and applied for preclinical and clinical studies. Clinical trials were performed for both malignant and nonmalignant diseases. Breast cancer, glioma, and lung cancer were malignant, and myocardial infarction, atherosclerosis, and moyamoya disease were nonmalignant among the investigated diseases. Further, these 68Ga-labeled RGD derivatives could be applied to assess the effects of antiangiogenic treatment or theragnosis or both, of cancers. In conclusion, the angiogenesis imaging technology using 68Ga-labeled RGD derivatives might be useful for the development of new therapeutic assessments, and for diagnostic and theragnostic applications.

Original languageEnglish
Pages (from-to)419-427
Number of pages9
JournalSeminars in Nuclear Medicine
Volume46
Issue number5
DOIs
Publication statusPublished - 2016 Sep 1

Fingerprint

Lung Neoplasms
Vascular Tissue Neoplasms
Moyamoya Disease
Integrins
Glioma
Radioisotopes
Cost-Benefit Analysis
Atherosclerosis
Therapeutics
Myocardial Infarction
Clinical Trials
Breast Neoplasms
Technology
Neoplasms
arginyl-glycyl-aspartic acid
Clinical Studies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Angiogenesis Imaging Using 68Ga-RGD PET/CT : Therapeutic Implications. / Eo, Jae Seon; Jeong, Jae Min.

In: Seminars in Nuclear Medicine, Vol. 46, No. 5, 01.09.2016, p. 419-427.

Research output: Contribution to journalReview article

@article{e4e74a98ba9448aab638099b6050b985,
title = "Angiogenesis Imaging Using 68Ga-RGD PET/CT: Therapeutic Implications",
abstract = "Angiogenesis imaging is important for diagnostic and therapeutic treatment of various malignant and nonmalignant diseases. The Arg-Gly-Asp (RGD) sequence has been known to bind with the αvβ3 integrin that is expressed on the surface of angiogenic blood vessels or tumor cells. Thus, various radiolabeled derivatives of RGD peptides have been developed for angiogenesis imaging. Among the various radionuclides, 68Ga was the most widely studied for RGD peptide imaging because of its excellent nuclear physical properties, easy-to-label chemical properties, and cost-effectiveness owing to the availability of a 68Ge-68Ga generator. Thus, various 68Ga-labeled RGD derivatives have been developed and applied for preclinical and clinical studies. Clinical trials were performed for both malignant and nonmalignant diseases. Breast cancer, glioma, and lung cancer were malignant, and myocardial infarction, atherosclerosis, and moyamoya disease were nonmalignant among the investigated diseases. Further, these 68Ga-labeled RGD derivatives could be applied to assess the effects of antiangiogenic treatment or theragnosis or both, of cancers. In conclusion, the angiogenesis imaging technology using 68Ga-labeled RGD derivatives might be useful for the development of new therapeutic assessments, and for diagnostic and theragnostic applications.",
author = "Eo, {Jae Seon} and Jeong, {Jae Min}",
year = "2016",
month = "9",
day = "1",
doi = "10.1053/j.semnuclmed.2016.04.001",
language = "English",
volume = "46",
pages = "419--427",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Angiogenesis Imaging Using 68Ga-RGD PET/CT

T2 - Therapeutic Implications

AU - Eo, Jae Seon

AU - Jeong, Jae Min

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Angiogenesis imaging is important for diagnostic and therapeutic treatment of various malignant and nonmalignant diseases. The Arg-Gly-Asp (RGD) sequence has been known to bind with the αvβ3 integrin that is expressed on the surface of angiogenic blood vessels or tumor cells. Thus, various radiolabeled derivatives of RGD peptides have been developed for angiogenesis imaging. Among the various radionuclides, 68Ga was the most widely studied for RGD peptide imaging because of its excellent nuclear physical properties, easy-to-label chemical properties, and cost-effectiveness owing to the availability of a 68Ge-68Ga generator. Thus, various 68Ga-labeled RGD derivatives have been developed and applied for preclinical and clinical studies. Clinical trials were performed for both malignant and nonmalignant diseases. Breast cancer, glioma, and lung cancer were malignant, and myocardial infarction, atherosclerosis, and moyamoya disease were nonmalignant among the investigated diseases. Further, these 68Ga-labeled RGD derivatives could be applied to assess the effects of antiangiogenic treatment or theragnosis or both, of cancers. In conclusion, the angiogenesis imaging technology using 68Ga-labeled RGD derivatives might be useful for the development of new therapeutic assessments, and for diagnostic and theragnostic applications.

AB - Angiogenesis imaging is important for diagnostic and therapeutic treatment of various malignant and nonmalignant diseases. The Arg-Gly-Asp (RGD) sequence has been known to bind with the αvβ3 integrin that is expressed on the surface of angiogenic blood vessels or tumor cells. Thus, various radiolabeled derivatives of RGD peptides have been developed for angiogenesis imaging. Among the various radionuclides, 68Ga was the most widely studied for RGD peptide imaging because of its excellent nuclear physical properties, easy-to-label chemical properties, and cost-effectiveness owing to the availability of a 68Ge-68Ga generator. Thus, various 68Ga-labeled RGD derivatives have been developed and applied for preclinical and clinical studies. Clinical trials were performed for both malignant and nonmalignant diseases. Breast cancer, glioma, and lung cancer were malignant, and myocardial infarction, atherosclerosis, and moyamoya disease were nonmalignant among the investigated diseases. Further, these 68Ga-labeled RGD derivatives could be applied to assess the effects of antiangiogenic treatment or theragnosis or both, of cancers. In conclusion, the angiogenesis imaging technology using 68Ga-labeled RGD derivatives might be useful for the development of new therapeutic assessments, and for diagnostic and theragnostic applications.

UR - http://www.scopus.com/inward/record.url?scp=84983030811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983030811&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2016.04.001

DO - 10.1053/j.semnuclmed.2016.04.001

M3 - Review article

C2 - 27553467

AN - SCOPUS:84983030811

VL - 46

SP - 419

EP - 427

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 5

ER -